18 stories mentioning TEVAUpdated 37d ago
Every FINWIRES story that references TEVA, newest first.
Matthew Shields, Executive Vice President, Global Operations, on June 18, 2026, sold 9,989 shares in Teva Pharmaceutical Industries (TEVA) for $321,547.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526277490/xslF345X05/ownership.xml
Eliyahu Sharon Kalif, Executive Vice President and Chief Financial Officer, on June 11, 2026, sold 106,563 shares in Teva Pharmaceutical Industries (TEVA) for $3,633,308. Following the Form 4 filing with the SEC, Kalif has control over a total of 65,621 ordinary shares of the company, with 65,621 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526271862/xslF345X05/ownership.xml
Alvotech (ALVO) said Monday the US Food and Drug Administration has agreed to review its licensing application for a proposed interchangeable biosimilar to the biologic medicine Entyvio for the treatment of ulcerative colitis and Crohn's disease.The company is responsible for developing, as well as producing the medication, while Teva Pharmaceutical (TEVA) oversees market distribution, the company said.The submission has testing data to provide the biological equivalence between the proposed alternative therapy and the original.A prior trial testing a separate variation of the treatment successfully achieved all primary targets to serve as the core clinical similarity evidence for both formulations.Shares of Alvotech added more than 4% in Monday premarket activity.Price: $3.71, Change: $+0.17, Percent Change: +4.90%
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) declined 1%.In corporate news, Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows Austedo and Austedo XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers. Teva Pharmaceutical shares were up 0.8%.BioCardia (BCDA) said it has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed more than 24%.Edesa Biotech (EDSA) said Friday that new data showed that paridiprubart combined with standard of care treatments was associated with a 32% relative reduction in mortality in patients with acute kidney injury and respiratory distress at 28 days. Edesa Biotech shares dropped 22.4%.
Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows AUSTEDO tablets and AUSTEDO XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers.Huntington's disease is a fatal neurodegenerative disease characterized by uncontrollable movements as well as behavioral and/or psychological problems, the company said, adding that chorea is one of the most striking physical manifestations of the disease and occurs in about 90% of patients.The survey data found that more than 68% of patients reported chorea affected their social life or emotional well-being, while up to 83% of caregivers reported disruptions to their own daily lives, the company said.After treatment with AUSTEDO or AUSTEDO XR, 60% to 71% of patients reported improvements in quality of life due to better movement control, and as a result, caregivers also reported less impact on their daily lives, the company added.Shares of Teva Pharmaceutical Industries rose nearly 1.4% in Friday's trading.Price: $34.96, Change: $+0.53, Percent Change: +1.54%
Veeva Systems (VEEV) said Wednesday that Teva Pharmaceutical (TEVA) and Germany-based Merck KGaA have committed to use its Vault CRM software globally.Vault CRM is an application for life sciences companies that connects sales, marketing, and medical teams on a single platform, Veeva said.Financial terms of the agreements were not disclosed.Shares of Veeva were up by more than 3% in Wednesday trading.Price: $163.01, Change: $+4.47, Percent Change: +2.82%
Teva Pharmaceutical Industries' (TEVA) marketing authorization application for olanzapine long-acting injectable for the treatment of schizophrenia in adults has been accepted by the European Medicines Agency, the company said Thursday.The drug, named TEV-749, aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.The application is supported by an extensive clinical development program, in which the drug demonstrated efficacy, a systemic safety profile, and exposure consistent with oral olanzapine, Teva said.Shares of Teva were down 1.4% in Thursday trading.Price: $33.82, Change: $-0.50, Percent Change: -1.46%
Eliyahu Sharon Kalif, Executive Vice President, Chief Financial Officer, on May 14, 2026, sold 153,251 shares in Teva Pharmaceutical Industries (TEVA) for $5,457,375. Following the Form 4 filing with the SEC, Kalif has control over a total of 172,184 ordinary shares of the company, with 172,184 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526228870/xslF345X05/ownership.xml
Evan Lippman, Executive Vice President, Business Development, on May 14, 2026, sold 41,658 shares in Teva Pharmaceutical Industries (TEVA) for $1,482,367. Following the Form 4 filing with the SEC, Lippman has control over a total of 44,191 ordinary shares of the company, with 44,191 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526228876/xslF345X05/ownership.xml
Richard Daniell, Executive Vice President, Europe Commercial, on May 05, 2026, sold 30,000 shares in Teva Pharmaceutical Industries (TEVA) for $1,062,000. Following the Form 4 filing with the SEC, Daniell has control over a total of 55,755 ordinary shares of the company, with 55,755 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211833/xslF345X05/ownership.xml
Amir Weiss, Chief Accounting Officer, on May 06, 2026, sold 10,679 shares in Teva Pharmaceutical Industries (TEVA) for $384,444. Following the Form 4 filing with the SEC, Weiss has control over a total of 20,016 ordinary shares of the company, with 20,016 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211855/xslF345X05/ownership.xml
Mark Sabag, Executive Vice President, International Markets Commercial, on May 01, 2026, sold 144,180 shares in Teva Pharmaceutical Industries (TEVA) for $5,045,118. Following the Form 4 filing with the SEC, Sabag has control over a total of 80,760 ordinary shares of the company, with 80,760 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526203928/xslF345X05/ownership.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $42 from $36, 13.6x our 2027 EPS forecast of $3.09, aboveTEVA's historical forward P/E average, justified in our view, by its improving growth prospects. We lower our 2026 EPS estimate to $2.11 from $2.77 to adjust for the Emalex acquisition impact. We keep our 2027 EPS estimate at $3.09. Teva reported a solid Q1, beating expectations, driven by the continued strong performance of its innovative growth engines (AUSTEDO, AJOVY, and UZEDY) which collectively grew 41% and are successfully offsetting the anticipated revenue decline from the loss of exclusivity for the generic REVLIMID. The newly announced $700M Emalex acquisition, expected to close in Q3, is a significant strategic move, and a major positive, in our view. The deal will bring the NDA-ready, first-in-class lead asset Ecopipam to treat Tourette syndrome, which has a significant unmet need, into Teva's neuroscience pipeline. We think the acquisition can accelerate TEVA's shift toward innovative, high-margin products.
Teva Pharmaceutical Industries (TEVA) could see further upside as its valuation re-rates, supported by "expanding branded growth" and pipeline strength following its Q1 results, UBS Securities said in a report Thursday.The firm said confidence in the company's growth profile has improved on a broadening pipeline, including the Emalex Biosciences acquisition, and rising investor "appetite" for de-risked biopharma names, while the company is emerging as a rare mix of "affordable valuation" and branded growth potential, with easing geopolitical concerns after it flagged no "material operational impact."The firm also highlighted "shareholder-friendly capital allocation," noting that Teva has accelerated its business development strategy and is considering potential share buybacks earlier than "previously guided."The company's management has signaled openness to additional deals, alongside plans to reduce leverage to below 2x net debt to EBITDA by 2027 and achieve investment-grade status by 2026, according to the report.UBS has a buy rating on Teva Pharmaceutical and raised its price target to $42 from $36.Price: $35.15, Change: $-0.23, Percent Change: -0.65%
Teva Pharmaceutical Industries (TEVA) has an average rating of buy and mean price target of $41.89 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $35.09, Change: $-0.29, Percent Change: -0.82%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Teva delivered solid Q1 2026 results with revenue of $3,982M (+2% Y/Y) and non-GAAP EPS of $0.53, beating consensus estimates of $0.46. The innovative portfolio drove growth with key brands generating $838M (+41% Y/Y), led by AUSTEDO at $578M (+41%), AJOVY at $196M (+35%), and UZEDY at $63M (+62%). This strong momentum in neuroscience products demonstrates the success of Teva's Pivot to Growth strategy, offsetting generics headwinds from lenalidomide competition. Management maintained 2026 revenue guidance of $16.4B-$16.8B but updated EPS expectations to $1.91-$2.11 due to the strategic $700M acquisition of Emalex Biosciences. The Emalex transaction adds ecopipam, a first-in-class treatment for pediatric Tourette syndrome with NDA submission expected in H2 2026. We believe this acquisition aligns with Teva's neuroscience focus and represents capital-efficient pipeline expansion; it will impact near-term margins with the expected IPR&D charge.
Health care stocks were mixed pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.1%.Teva Pharmaceutical Industries (TEVA) shares were up more than 8% after the company posted higher Q1 non-GAAP earnings and net revenue.AstraZeneca (AZN) stock was down more than 1% even after the company reported higher Q1 core earnings and revenue.GE Healthcare Technologies (GEHC) shares were down more than 9% after the company posted a decline in Q1 adjusted earnings, and cut its 2026 adjusted EPS outlook.
Health care stocks were mixed pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% lower and the iShares Biotechnology ETF (IBB) up 0.1%.Teva Pharmaceutical Industries (TEVA) shares were up more than 9% after the company posted higher Q1 non-GAAP earnings and net revenue.
